Company Overview and News

 
Nikkei falls on Hokkaido quake; spotlight on reshuffled benchmark stocks

2018-09-06 reuters
TOKYO, Sept 6 (Reuters) - Japan’s Nikkei fell on Thursday on the back of broad weakness in global equities, while investors awaited damage assessments after a powerful earthquake in Hokkaido, the latest in a series of natural disasters to hit the country this year.
JPXGY 9681 2531 OSCUF TKHIY 8697 TOZOF

 
BTS takes on first Japan dome tour

2018-07-31 entertainment.inquirer.net
Another milestone will be added to K-pop phenomenon BTS’ list as they are set to hold their first Japanese dome tour, a part of their “Love Yourself” world tour.
9681 WU

 
Nikkei rises to more than 1-month high; automakers, tech shares gain

2018-07-18 reuters
TOKYO, July 18 (Reuters) - Japan’s Nikkei share average advanced to a more than one-month high on Wednesday as exporters such as automakers and technology firms got a boost after the dollar hit a six-month high against the yen.
7261 9681 ADTTF MZDAY TM TYT TOYOF 2531 TTDKF TKHIY MZDAF 7203 ATEYY

 
Nikkei jumps to over 1-month high

2018-07-18 thehindubusinessline
Japan's Nikkei share average soared to a more than one-month high on Wednesday morning as exporters such as automakers and technology firms got a boost after the dollar hit a six-month high against the yen.
7261 PCRFY 9681 ADTTF MZDAY TM TYT TOYOF 2531 TTDKF TKHIY MZDAF 7203 ATEYY

 
Nikkei rises to more than 1-month high as exporters get boost from weak yen

2018-07-18 reuters
* Takara, Tokyo Dome fall after brokerage takes guess to be excluded from Nikkei index in Oct
7261 PCRFY 9681 ADTTF MZDAY TM TYT TOYOF 2531 TTDKF TKHIY MZDAF 7203 ATEYY

57
In One of the World’s Richest Countries, Most Single Mothers Live in Poverty - Bloomberg

2018-06-25 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
JBK 9681 GSC TFG DSECF GSJ GS GLSSP 8601 DSEEY GJS

 
Flash - Yankees, Red Sox to clash in London in 2019 - France 24

2018-05-08 france24
The New York Yankees and Boston Red Sox will clash in the first Major League Baseball games in Europe next year as the sport looks to grow its global fanbase, MLB chiefs announced on Tuesday.
9681

 
BRIEF-Tokyo Dome's Operating Profit Looks To Have Fallen 10 Pct For Year Ended In January - Nikkei

2018-03-12 reuters
* TOKYO DOME CORP’S OPERATING PROFIT LOOKS TO HAVE FALLEN 10 PERCENT TO A LITTLE OVER 11 BILLION YEN FOR THE YEAR ENDED IN JANUARY - NIKKEI
9681

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...